Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Health DOI
Michael A. Raddatz, Yash Pershad, Alyssa Parker

et al.

Cardiology Clinics, Journal Year: 2024, Volume and Issue: 43(1), P. 13 - 23

Published: Oct. 2, 2024

Language: Английский

Biomarkers in clonal haematopoiesis of indeterminate potential (CHIP) linking cardiovascular diseases, myeloid neoplasms and inflammation DOI Creative Commons

Hongtao Tan,

Haowen Jiang, Samuel Sherng Young Wang

et al.

Annals of Hematology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 24, 2025

Language: Английский

Citations

0
Clonal Hematopoiesis, a Risk Condition for Developing Myeloid Neoplasia DOI Creative Commons
Ugo Testa, Germana Castelli, Elvira Pelosi

et al.

Hemato, Journal Year: 2025, Volume and Issue: 6(2), P. 10 - 10

Published: April 22, 2025

Clonal hematopoiesis (CH) is an age-related process in which hematopoietic stem/progenitor cells increase their fitness due to the acquisition of mutations that lead a proliferative advantage and clonal expansion. Its frequency increases with age, it mostly affects people older than 70 years. The most mutated genes CH are epigenetic regulators, DNA damage response genes, splicing factors, all involved development myeloid neoplasia. Some risk including smoking, prior cytotoxic therapy, developing or CH. Various types have been observed, associated not cytopenias monocytosis. represents factor for many pathological conditions particularly hematologic malignancies. A better understanding risks related has triggered research, translational, clinical programs monitoring, prevention, treatment

Language: Английский

Citations

0
A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis DOI Creative Commons
Tamanna Haque, Aditi Shastri, Pinkal Desai

et al.

British Journal of Haematology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 9, 2024

The age-associated mutational state of clonal haematopoiesis (CH) is linked to multiple adverse health outcomes. As higher risk CH can lead progressive neoplastic or vascular disease, there interest in developing clinical trials mitigate associated with CH. Given the high prevalence CH, data from could have broad public implications for screening and therapy. Thoughtful consideration needed design that are both clinically relevant avoid overmedicalization. Here, we summarize studies date provide suggestions guidance on how approach designing CH-focused therapeutic trials. These recommendations derived discussions among researchers scientists emanating Inaugural Meeting Somatic Mutations Predisease October 2021.

Language: Английский

Citations

1
Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Health DOI
Michael A. Raddatz, Yash Pershad, Alyssa Parker

et al.

Cardiology Clinics, Journal Year: 2024, Volume and Issue: 43(1), P. 13 - 23

Published: Oct. 2, 2024

Language: Английский

Citations

0